Tenaya Narrows Losses, Boosts Cash Amid R&D Streamlining

TL;DR

**Tenaya's cash injection and cost cuts are a lifeline, but they're still burning through capital, so watch for clinical trial data before jumping in.**

AI Summary

Tenaya Therapeutics, Inc. reported a net loss of $20.275 million for the three months ended September 30, 2025, a 20.8% improvement from the $25.634 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $70.422 million, a 19.4% reduction from $87.293 million in 2024. Research and development expenses decreased significantly to $15.363 million for the three months ended September 30, 2025, down from $20.350 million in 2024, and to $53.809 million for the nine months, down from $68.054 million. General and administrative expenses also saw a reduction, falling to $5.573 million for the quarter and $18.747 million for the nine months. The company's cash and cash equivalents increased substantially to $56.312 million as of September 30, 2025, from $4.323 million at December 31, 2024, bolstered by $48.8 million in net proceeds from a March 2025 follow-on offering. Tenaya implemented a workforce reduction in March 2025 to focus on clinical trials for TN-201 and TN-401, and management believes existing capital, along with a $10.0 million available draw from Silicon Valley Bank and $1.9 million from October 2025 warrant exercises, will fund operations for at least the next twelve months.

Why It Matters

Tenaya's reduced net loss and increased cash position are critical for investors, signaling improved financial discipline and extended runway for its clinical-stage programs, TN-201 and TN-401. The workforce reduction, while impacting employees, demonstrates a strategic focus on core assets, which could enhance competitive positioning against larger biotech firms in the heart disease space. For customers, continued funding means potential progress on novel gene therapies for serious heart conditions. The broader market will watch if these cost containment measures translate into accelerated clinical milestones, potentially validating the company's gene therapy platform.

Risk Assessment

Risk Level: medium — The company has an accumulated deficit of $584.8 million as of September 30, 2025, and continues to incur net losses, including $70.4 million for the nine months ended September 30, 2025. While management believes current funds will last at least 12 months, they explicitly state the need to raise additional capital, indicating ongoing financial dependency and dilution risk.

Analyst Insight

Investors should monitor Tenaya's upcoming clinical trial data for TN-201 and TN-401, as these milestones are crucial for future financing and valuation. Given the explicit need for additional capital, investors should also assess the potential for further equity dilution and the terms of any future financing rounds.

Financial Highlights

net Income

-$20.275M

cash Position

$56.312M

Key Numbers

• $70.4M — Net Loss (for the nine months ended September 30, 2025, a 19.4% reduction from $87.3M in 2024)
• $56.3M — Cash and Cash Equivalents (as of September 30, 2025, up from $4.3M at December 31, 2024)
• $48.8M — Net Proceeds (from March 2025 follow-on offering)
• $53.8M — Research and Development Expenses (for the nine months ended September 30, 2025, down from $68.1M in 2024)
• $584.8M — Accumulated Deficit (as of September 30, 2025)
• $10.0M — Available Funds (from Loan Agreement with Silicon Valley Bank)

Key Players & Entities

• Tenaya Therapeutics, Inc. (company) — clinical-stage biotechnology company
• Silicon Valley Bank (company) — lender for Loan Agreement
• TN-201 (product) — gene therapy for hypertrophic cardiomyopathy
• TN-401 (product) — gene therapy for arrhythmogenic right ventricular cardiomyopathy
• TN-301 (product) — small molecule for heart failure with preserved ejection fraction
• SEC (regulator) — Securities and Exchange Commission
• FDA (regulator) — U.S. Food and Drug Administration

FAQ

Risk Factors

• Substantial doubt about going concern [high — financial]: The company has incurred significant net losses and an accumulated deficit of $584.8 million as of September 30, 2025. While management believes current capital and available credit lines will fund operations for at least the next twelve months, the ability to achieve profitability and secure future funding remains a significant risk.
• Reliance on clinical trial success [high — operational]: Tenaya's future success is heavily dependent on the successful development and commercialization of its product candidates, particularly TN-201 and TN-401. Delays, adverse results, or regulatory hurdles in clinical trials could materially impact the company's financial condition and prospects.
• Drug development and regulatory approval [high — regulatory]: The development of new drugs is a lengthy, expensive, and uncertain process. Obtaining regulatory approval from bodies like the FDA is a complex and time-consuming process, and there is no guarantee that Tenaya's product candidates will receive approval.
• Competition in the biotechnology sector [medium — market]: The biotechnology industry is highly competitive, with many companies developing therapies for similar diseases. Tenaya faces competition from established pharmaceutical companies and emerging biotech firms, which could affect market share and pricing.
• Need for future financing [medium — financial]: The company has historically relied on equity financings to fund its operations. If Tenaya is unable to secure additional funding in the future, it may be forced to curtail its research and development activities or delay its product development timelines.
• Workforce reduction impact [medium — operational]: The March 2025 workforce reduction, while aimed at focusing resources, could potentially impact the company's ability to execute its development plans and retain key talent.

Industry Context

Tenaya Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, focusing on developing therapies for cardiovascular diseases. The industry is characterized by significant R&D investment, long development cycles, and a high rate of failure. Companies like Tenaya compete with both established pharmaceutical giants and numerous other biotech startups vying for market share and investor capital.

Regulatory Implications

As a clinical-stage biotechnology company, Tenaya is subject to stringent regulatory oversight from bodies like the FDA. The success of its product candidates hinges on navigating complex clinical trial pathways and obtaining regulatory approval, which can be a lengthy and uncertain process. Any delays or adverse findings in trials could have significant financial and operational repercussions.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for TN-201 and TN-401.
2. Assess the company's cash burn rate and runway.
3. Evaluate the competitive landscape and Tenaya's differentiation.

Key Dates

• 2025-03-01: Follow-on offering completed — Provided $48.8 million in net proceeds, significantly bolstering the company's cash position and extending its operational runway.
• 2025-03-01: Workforce reduction implemented — A strategic move to focus resources on key clinical trials (TN-201 and TN-401), potentially improving operational efficiency but carrying risks related to talent and execution.
• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing a reduced net loss and increased cash balance compared to prior periods.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Tenaya has an accumulated deficit of $584.8 million as of September 30, 2025, highlighting its history of losses and reliance on external funding.)

Follow-on offering

A public offering by a company that has already issued stock in an initial public offering (IPO). It allows the company to raise additional capital by selling more shares. (Tenaya raised $48.8 million in net proceeds from a follow-on offering in March 2025, which significantly improved its cash position.)

Net Proceeds

The amount of money a company receives from an issuance or sale of securities after deducting any underwriting discounts, commissions, and offering expenses. (The $48.8 million in net proceeds from the follow-on offering is a key factor in Tenaya's improved cash position.)

Going Concern

A business's ability to continue operating for the foreseeable future. If there is substantial doubt about a company's ability to continue as a going concern, it must be disclosed. (The company's financial condition, including its accumulated deficit and net losses, raises substantial doubt about its ability to continue as a going concern, although management believes it has sufficient capital for the next twelve months.)

Year-Over-Year Comparison

Tenaya Therapeutics has demonstrated a reduction in net losses for both the three-month and nine-month periods ended September 30, 2025, compared to the prior year, indicating improved cost management. Research and development expenses have also decreased, reflecting a strategic focus. The company's cash position has significantly improved, largely due to a successful follow-on offering, which provides a more robust financial runway. However, the accumulated deficit remains substantial, and the company continues to operate at a loss, underscoring the inherent risks in drug development.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select

Filing Documents

• tnya-20250930.htm (10-Q) — 2601KB
• tnya-ex4_1.htm (EX-4.1) — 133KB
• tnya-ex31_1.htm (EX-31.1) — 22KB
• tnya-ex32_1.htm (EX-32.1) — 10KB
• 0001193125-25-273239.txt ( ) — 8977KB
• tnya-20250930.xsd (EX-101.SCH) — 1102KB
• tnya-20250930_htm.xml (XML) — 1446KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 6 Condensed Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 7 Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 9 Notes to Unaudited Condensed Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 87 Item 3. Defaults Upon Senior Securities 87 Item 4. Mine Safety Disclosures 87 Item 5. Other Information 87 Item 6. Exhibits 88

SIGNATURES

SIGNATURES 89 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report), contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, investors can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements include, but are not limited to, statements about: our vision to change the treatment paradigm for heart disease; the ability of our ongoing preclinical studies and ongoing or planned clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing, dosing, patient enrollment and populations, progress, and results of preclinical studies and ongoing or planned clinical trials for our current product candidates and other product candidates we may develop; the timing, scope and likelihood of regulatory filings and approvals, including timing of investigational new drugs (INDs), clinical trial applications (CTAs), U.S. Food and Drug Administration (FDA) approvals, and final regulatory approval of our current product candidates and any othe

– FINANC IAL INFORMATION

PART I – FINANC IAL INFORMATION

Financi al Statements

Item 1. Financi al Statements. TENAYA THERAPEUTICS, INC. Condensed Ba lance Sheets (In thousands) (Unaudited) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 56,312 $ 4,323 Short-term investments in marketable securities — 57,123 Prepaid expenses and other current assets 4,927 5,929 Total current assets 61,239 67,375 Property and equipment, net 29,440 35,858 Operating lease right-of-use assets 10,057 11,890 Other noncurrent assets 4,244 4,817 Total assets $ 104,980 $ 119,940 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,843 $ 5,162 Accrued and other current liabilities 7,441 8,035 Operating lease liabilities, current 2,926 2,778 Total current liabilities 13,210 15,975 Operating lease liabilities, noncurrent 8,601 10,830 Other noncurrent liabilities 301 281 Total liabilities 22,112 27,086 Commitments and contingencies (Note 4) Stockholders' equity: Common stock 16 8 Additional paid-in capital 667,685 607,229 Accumulated other comprehensive income (loss) — 28 Accumulated deficit ( 584,833 ) ( 514,411 ) Total stockholders' equity 82,868 92,854 Total liabilities and stockholders' equity $ 104,980 $ 119,940 The accompanying notes are an integral part of these unaudited condensed financial statements. 5 TENAYA THERAPEUTICS, INC. Condensed Statements of Opera tions and Comprehensive Loss (In thousands, except share and per share data) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 15,363 $ 20,350 $ 53,809 $ 68,054 General and administrative 5,573 6,361 18,747 23,242 Total operating expenses 20,936 26,711 72,556 91,296 Loss from operations ( 20,936 ) ( 26,711 )